Search research articles
Contact Us
Filters
Showing results (311-320 of 3,459) with videos related to
Page
of 346
Sort By:
JACC. Basic to Translational Science
|
December 14, 2023
Inhibiting Serotonin to Treat Pulmonary Arterial Hypertension: An Exciting New Chapter in an Old Story
Bradley A Maron
Clinical Therapeutics
|
November 6, 2024
Silver Linings: Side Effects and Secondary Findings of Newly Emerging Therapies
Jill L Maron
Clinical Therapeutics
|
August 17, 2025
Now What? Utilizing Adverse Drug Reporting Databases to Inform Care, Update Guidelines, and Improve Outcomes
Jill L Maron
Clinical Therapeutics
|
March 12, 2023
Weighing in on the Scale of Justice for Equity and Access to Weight-management Drugs
Jill L Maron
Current Opinion in Pulmonary Medicine
|
July 7, 2025
Precision medicine in pulmonary hypertension: how close are we today?
Bradley A Maron
Clinical Therapeutics
|
February 18, 2026
The Use of Ensemble Large Language Models to Predict Patient Nonadherence
Jill L Maron
Circulation
|
July 6, 2026
A New <i>Circulation</i>, For You
Bradley A Maron
Heart (British Cardiac Society)
|
October 21, 2022
Differing strategies for sudden death prevention in hypertrophic cardiomyopathy
Martin S Maron, Ethan Rowin, Paolo Spirito, et al.
The American Journal of Cardiology
|
February 24, 2018
Is It Fair to Screen Only Competitive Athletes for Sudden Death Risk, or Is It Time to Level the Playing Field?
Barry J Maron, N A Mark Estes, Martin S Maron
Journal of the American College of Cardiology
|
October 21, 2015
Reply: What Is the True Prevalence of Hypertrophic Cardiomyopathy?
Christopher Semsarian, Jodie Ingles, Martin S Maron, et al.
Page
of 346
Search research articles
Search
Showing results (311-320 of 3,459) with videos related to
Sort By:
Page
of 346
JACC. Basic to Translational Science
|
December 14, 2023
Inhibiting Serotonin to Treat Pulmonary Arterial Hypertension: An Exciting New Chapter in an Old Story
Bradley A Maron
Clinical Therapeutics
|
November 6, 2024
Silver Linings: Side Effects and Secondary Findings of Newly Emerging Therapies
Jill L Maron
Clinical Therapeutics
|
August 17, 2025
Now What? Utilizing Adverse Drug Reporting Databases to Inform Care, Update Guidelines, and Improve Outcomes
Jill L Maron
Clinical Therapeutics
|
March 12, 2023
Weighing in on the Scale of Justice for Equity and Access to Weight-management Drugs
Jill L Maron
Current Opinion in Pulmonary Medicine
|
July 7, 2025
Precision medicine in pulmonary hypertension: how close are we today?
Bradley A Maron
Clinical Therapeutics
|
February 18, 2026
The Use of Ensemble Large Language Models to Predict Patient Nonadherence
Jill L Maron
Circulation
|
July 6, 2026
A New <i>Circulation</i>, For You
Bradley A Maron
Heart (British Cardiac Society)
|
October 21, 2022
Differing strategies for sudden death prevention in hypertrophic cardiomyopathy
Martin S Maron, Ethan Rowin, Paolo Spirito, et al.
The American Journal of Cardiology
|
February 24, 2018
Is It Fair to Screen Only Competitive Athletes for Sudden Death Risk, or Is It Time to Level the Playing Field?
Barry J Maron, N A Mark Estes, Martin S Maron
Journal of the American College of Cardiology
|
October 21, 2015
Reply: What Is the True Prevalence of Hypertrophic Cardiomyopathy?
Christopher Semsarian, Jodie Ingles, Martin S Maron, et al.
Page
of 346